Patent ID: 6335174
Filing Date: 2002-01-01
Classification: A61P,C07K,G01N,Y10S

Abstract:
A method of determining whether cancer treatment is successful, comprising:obtaining a sample of T-lymphocytes from a cancer patient undergoing cancer therapy; wherein said cancer is characterized by expression of 44 kD oncofetal antigen (OFA); cloning said T-lymphocytes including CD8 cytotoxic T-lymphocytes and T-cells making IL-10, wherein cloned T-lymphocytes comprise OFA-specific T-cells; contacting said T-lymphocytes with a composition comprising the 44 kD OFA, thereby stimulating said OFA-specific T-cells; and determining the relative frequency of said OFA-specific T-cells making IL-10 to said OFA -specific CD8 cytotoxic T-cells, wherein when said frequency of said OFA-specific CD8 cytotoxic T-cells is high and said frequency of said OFA-specific T-cells making IL-10 is low, said cancer therapy is successful.